Mechanism studies have shown that the anti-tumor effect of the combination therapy group may be related to immune cell infiltration, CAR-T cell infiltration, and upregulation of immune related factors.<h4>Conclusion</h4>Our findings demonstrated the potential of TROP-2 as a viable target for CAR-T therapy in breast cancer. The gene discussed is TACSTD2; the disease is breast cancer.